Jérôme Dauba

4.3k total citations
54 papers, 1.3k citations indexed

About

Jérôme Dauba is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Physiology. According to data from OpenAlex, Jérôme Dauba has authored 54 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 8 papers in Physiology. Recurrent topics in Jérôme Dauba's work include Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (21 papers) and Lung Cancer Treatments and Mutations (10 papers). Jérôme Dauba is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Colorectal Cancer Treatments and Studies (21 papers) and Lung Cancer Treatments and Mutations (10 papers). Jérôme Dauba collaborates with scholars based in France, Austria and Canada. Jérôme Dauba's co-authors include Pierre Soubeyran, J. Ceccaldi, Laurent Cany, C. Blanc-Bisson, Nadine Houédé, Marianne Fonck, Jean‐Frédéric Blanc, C. Mertens, M. Rainfray and Carine Bellera and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Jérôme Dauba

52 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jérôme Dauba France	14	738	497	363	355	199	54	1.3k
Laurent Cany France	15	709 1.0×	336 0.7×	350 1.0×	332 0.9×	129 0.6×	38	1.2k
Jean-Pierre Droz France	12	795 1.1×	575 1.2×	520 1.4×	340 1.0×	383 1.9×	12	2.0k
V. Servent France	12	610 0.8×	352 0.7×	300 0.8×	224 0.6×	213 1.1×	30	1.2k
Nicolò Matteo Luca Battisti United Kingdom	21	922 1.2×	398 0.8×	359 1.0×	219 0.6×	111 0.6×	81	1.6k
Véronique Girre France	13	556 0.8×	291 0.6×	445 1.2×	260 0.7×	149 0.7×	21	1.1k
Antonella Venturino Italy	14	533 0.7×	279 0.6×	249 0.7×	139 0.4×	133 0.7×	57	953
Daan ten Bokkel Huinink Netherlands	15	468 0.6×	501 1.0×	137 0.4×	267 0.8×	149 0.7×	32	1.2k
A.N.M. Wymenga Netherlands	19	617 0.8×	240 0.5×	244 0.7×	194 0.5×	101 0.5×	41	1.1k
S. Klapper United States	5	561 0.8×	327 0.7×	708 2.0×	387 1.1×	157 0.8×	7	1.3k
Richard M. Levine United States	13	578 0.8×	329 0.7×	435 1.2×	244 0.7×	111 0.6×	34	1.2k

Countries citing papers authored by Jérôme Dauba

Since Specialization

Citations

This map shows the geographic impact of Jérôme Dauba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Dauba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Dauba more than expected).

Fields of papers citing papers by Jérôme Dauba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Dauba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Dauba. The network helps show where Jérôme Dauba may publish in the future.

Co-authorship network of co-authors of Jérôme Dauba

This figure shows the co-authorship network connecting the top 25 collaborators of Jérôme Dauba. A scholar is included among the top collaborators of Jérôme Dauba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jérôme Dauba. Jérôme Dauba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rousseau, Benoı̂t, Thierry Lecomte, Aurélien Lambert, et al.. (2023). Assessment of an emergency 14-day (d) integrative supportive care program (14-EISCP) followed by early chemotherapy (CTx) in symptomatic patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): A prospective ARCAD cohort study.. Journal of Clinical Oncology. 41(4_suppl). 700–700. 1 indexed citations

Guisier, Florian, Catherine Dubos‐Arvis, F. Viñas, et al.. (2020). Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology. 15(4). 628–636. 215 indexed citations

Delattre, Jean-François, Romain Cohen, Julie Henriques, et al.. (2020). Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). Journal of Clinical Oncology. 38(15). 1702–1710. 55 indexed citations

Bachet, Jean‐Baptiste, Pascal Hammel, Jérôme Desrame, et al.. (2019). Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. Cancer Medicine. 8(11). 5079–5088. 8 indexed citations

Quoix, Élisabeth, Clarisse Audigier-Valette, A. Lavolé, et al.. (2018). Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial. Annals of Oncology. 29. viii744–viii745.

Taı̈eb, Julien, Franck Bonnetain, Laurent Mineur, et al.. (2017). Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results. Annals of Oncology. 28. v158–v158. 9 indexed citations

Trédan, Olivier, Philippe Follana, Isabelle Moullet, et al.. (2016). A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. Annals of Oncology. 27(6). 1020–1029. 19 indexed citations

Fiteni, Frédéric, Amélie Anota, Franck Bonnetain, et al.. (2016). Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy. European Respiratory Journal. 48(3). 861–872. 14 indexed citations

Brocard, Fabien, Marianne Leheurteur, Jérôme Dauba, et al.. (2016). Phase II trial evaluating the combination of eribulin (E)+ bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study. Annals of Oncology. 27. vi72–vi72. 1 indexed citations

10.

Pouessel, Damien, Sylvie Chevret, Frédéric Rolland, et al.. (2015). Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?. European Journal of Cancer. 54. 69–74. 11 indexed citations

11.

Chibaudel, Benoist, Olivier Bouché, Éveline Boucher, et al.. (2015). Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. Clinical Colorectal Cancer. 15(3). 250–256. 9 indexed citations

12.

Bourdel‐Marchasson, Isabelle, C. Blanc-Bisson, A. Doussau, et al.. (2014). Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial. PLoS ONE. 9(9). e108687–e108687. 98 indexed citations

13.

Hoppe, Stéphanie, M. Rainfray, Marianne Fonck, et al.. (2013). Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy. Journal of Clinical Oncology. 31(31). 3877–3882. 174 indexed citations

14.

Witte, S, et al.. (2013). Dermatomyosite secondaire à l’administration de trastuzumab (Herceptin ® ). Journal de Pharmacie Clinique. 32(1). 57–61.

15.

Weber, B., Rémy Largillier, Isabelle Ray‐Coquard, et al.. (2013). A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Supportive Care in Cancer. 21(7). 1947–1954. 8 indexed citations

16.

Soubeyran, Pierre, Marianne Fonck, C. Blanc-Bisson, et al.. (2012). Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer. Journal of Clinical Oncology. 30(15). 1829–1834. 305 indexed citations

17.

Durrieu, J., A. Doussau, Anja Rieger, et al.. (2012). DESIGN OF A PHYSICAL ACTIVITY PROGRAM TO PREVENT FUNCTIONAL DECLINE IN ONCO-GERIATRIC PATIENTS (CAPADOGE): A RANDOMIZED MULTICENTER TRIAL. The Journal of Frailty & Aging. 1(3). 1–6. 2 indexed citations

18.

Lortholary, Alain, R. Largillier, B. Weber, et al.. (2011). Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO). Annals of Oncology. 23(2). 346–352. 71 indexed citations

19.

Fonck, Marianne, René Brunet, Y. Bécouarn, et al.. (2011). Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: A first-line phase II study. Clinics and Research in Hepatology and Gastroenterology. 35(12). 823–830. 12 indexed citations

20.

Dauba, Jérôme, et al.. (1997). Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. European Journal of Cancer. 33(2). 297–300. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact